Project description
Overcoming technical obstacles in cell therapies
Despite the great promise of cell-based therapies, there are still technical limitations that prohibit their widespread application. The use of animal-derived products during the in vitro cell culture process poses a significant risk for immune responses and for the transmission of animal-borne diseases to transplanted patients. To address the need for animal-free culture media, the EU-funded PLATELYS proposes an innovative product based on human platelets. The platelet lysate is of clinical grade, having undergone quality control testing and can be employed for different cell therapies, including those using immune cells or stem cells.
Objective
Cellular therapies making use of stem cells, engineered immune cells or engineered tissue represent an unprecedented and fast-growing therapeutic area. To date, 14 cell therapies have been approved by the FDA. However, the cells being implanted to the patient need to be cultured in vitro at some point under highly specific and controlled conditions. One of these conditions –indispensable to culture any type of isolated cell in vitro– involves using animal-derived serum as a source of hormones and growth factors to mimic cells' native environment. It is estimated 1.5 million calf fetuses are inhumanely sacrificed to collect serum. This leads (among other negatives) to endanger patient's safety, because of cross-species immune reactions (which may be lethal) and the transmission of animal borne diseases (e.g. the mad cow disease). PlateLys is PLATOME´s solution to develop and produce a remarkable human-based serum substitute fulfilling all the requirements to culture cells. PLATOME is an award-winning Icelandic start-up created in 2016 to leverage the substantial know-how on human platelet lysates (hPL) production from its founders. PlateLys is the only hPL combining: a viral-inactivated hPL ensuring the highest safety profile for patients and operators; a clinical-grade lysate with standardized quality control and GMP certified amenable for research and clinical set-ups; a powder formulation providing maximal flexibility, especially on applications that were nonviable previously. The market of sera supplements will be worth €1.14 billion by 2025 (CAGR of 8%, period 2017-2025) with a large shift to hPL use ongoing. Through the PlateLys project we seek to complete the optimization and scale-up production, starting commercialization activities in Europe by 2021. By 2025, we will have generated €5.52 million in turnover and increase our staff by 300%. PlateLys will allow us to expand our portfolio of cell-oriented products, thanks to our patented production technology.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social sciencessociologyindustrial relationsautomation
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- engineering and technologyindustrial biotechnologybiomaterials
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
220 HAFNARFJORDUR
Iceland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.